Mankind Pharma Partners with Kotak and IIFL for Rs 3,000 Crore QIP to Fund BSV Deal
Mankind Pharma, India’s fourth-largest pharmaceutical company by domestic sales, has strategically moved forward with its Rs 13,630 crore acquisition of Bharat Serums and Vaccines (BSV). In a bold funding move, the pharma giant has partnered with Kotak Mahindra Capital and IIFL Capital to launch a Qualified Institutional Placement (QIP) worth up to Rs 3,000 crore,…
